Midface volumization and skin quality enhancement with a hyaluronic acid-polynucleotide hybrid filler: a 24-week prospective open-label study.

In 30 seconds

This single-center, prospective, open-label clinical trial evaluated a hyaluronic acid–polynucleotide hybrid filler in 15 adults with moderate-to-severe anteromedial cheek volume loss. Participants received up to 1 mL per side and were assessed through week 24 for cheek volume, aesthetic improvement, satisfaction, skin measures, and adverse events. Midface Volume Deficit Scale scores improved significantly by week 4 and remained improved at weeks 12 and 24; skin hydration and elasticity also improved, while transepidermal water loss decreased. All participants completed follow-up without serious adverse events.

Key findings

• Midface Volume Deficit Scale scores improved significantly at week 4 and remained improved through weeks 12 and 24.
• Global Aesthetic Improvement Scale and participant satisfaction scores showed gains alongside the volume improvements.
• Transepidermal water loss decreased, hydration increased, and Cutometer elasticity parameters R2, R5, and R7 progressively improved.
• All 15 participants completed the study without serious adverse events.

Why it matters

The findings suggest that this hybrid filler may provide both cheek-volume restoration and measurable improvements in skin barrier function, hydration, and elasticity. These outcomes are relevant because the study assessed skin quality alongside volumization, rather than volume alone. However, the results are preliminary and should be interpreted in light of the small, uncontrolled study design.

What to keep in mind

The study was single-center, open-label, and included only 15 participants; without a comparator, the findings cannot establish comparative efficacy.